Trial · NCT02868892
A Study of Pemetrexed in Recurrent Cervical Adenocarcinomas
NCT02868892, Phase 2, Terminated, Western Regional Medical Center; results first posted 2018-11-02
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Pemetrexed in Recurrent Cervical Adenocarcinomas. Trials, record NCT02868892. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02868892
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Pemetrexed in Recurrent Cervical Adenocarcinomas
- NCT number
- NCT02868892
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 6 participants, actual
- Lead sponsor
- Western Regional Medical Center
- Conditions
- Adenocarcinoma of the Cervix, Adenosquamous Cell Carcinoma of the Cervix
- Interventions
- Pemetrexed
- First posted
- 2016-08-16
- Last updated
- 2018-11-02
- Results first posted
- 2018-11-02
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression Free Survival | 2 years | Evaluate the progression free survival of recurrent cervical adenocarcinoma. Progression-Free Survival is defined as the period of time from the date of first study drug administration to the date that the subject is determined to have progressive disease or death due to any cause. |
| Secondary | Response Rate | 2 years | Evaluate the response rate for recurrent cervical adenocarcinomas treated with pemetrexed. Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension which must have been 20 mm when measured by conventional techniques including palpation, plain X-ray, CT, and MRI or 10 mm when measured by spiral CT. |
| Secondary | Overall Survival | 2 years | Evaluate Overall survival for recurrent cervical adenocarcinomas treated with pemetrexed. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Progression Free Survival | 2 years | Investigator no longer at site. Study was closed with no PI transfer, data collection or statistical analysis. | ||
| SECONDARY | Response Rate | 2 years | Investigator no longer at site. Study was closed with no PI transfer, data collection or statistical analysis. | ||
| SECONDARY | Overall Survival | 2 years | Investigator no longer at site. Study was closed with no PI transfer, data collection or statistical analysis. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Pemetrexed | 6 | |
| Overall Study | COMPLETED | Pemetrexed | 0 | |
| Overall Study | NOT COMPLETED | Pemetrexed | 6 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Pemetrexed | 0 | 6 |
| Total, other adverse events | Pemetrexed | 0 | 6 |
| Total, serious adverse events | Pemetrexed | 0 | 6 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02868892
GET https://conductscience.org/api/trials/v1/NCT02868892/registered